San Diego – – October 13, 2026 -- Inhibrx Biosciences (Nasdaq: INBX) will present phase 2 data on both clinical-stage candidates in its pipeline in four sessions at three oncology conferences between Oct. 25 and Nov. 20, 2026.
Ordastobart phase 2 primary analysis goes to ESMO on Oct. 25
The first session is an oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid on Sunday, Oct. 25, from 8:30 to 10:00 AM CET. Lead author Jong Chul Park will present the phase 2 primary analysis of HexAgon-HN, a phase 2/3 study of the hexavalent OX40 agonist ordastobart (INBRX-106) combined with pembrolizumab. The trial covers first-line treatment of PD-L1-high recurrent/metastatic head and neck squamous cell carcinoma.
Ozekibart chondrosarcoma data feature at MSTS and CTOS
On Thursday, Oct. 29, Robin Jones will give an oral presentation at the Musculoskeletal Tumor Society (MSTS) Annual Meeting in Miami, from 2:50 to 3:40 PM EST. He will present secondary efficacy endpoints for the tetravalent DR5 agonist ozekibart (INBRX-109) in conventional chondrosarcoma, drawn from the randomized, registrational phase 2 ChonDRAgon study.
At the Connective Tissue Oncology Society (CTOS) Annual Meeting in Seoul, Sant Chawla will present a subgroup analysis and updated progression-free survival from ChonDRAgon. The oral session is on Friday, Nov. 20, from 11:00 AM to 12:30 PM KST.
Ewing sarcoma combination study appears as a CTOS poster on Nov. 19
Varun Monga will present a poster on Thursday, Nov. 19, from 5:30 to 6:30 PM KST. It covers a phase 1/2 study of ozekibart combined with irinotecan and temozolomide in adolescents and adults with Ewing sarcoma.
Inhibrx will make the presentations and poster available through the investor section of its website once each event begins.